BOSTON (AP) — A Massachusetts pharmacist convicted for his role in a deadly 2012 meningitis outbreak fought through sobs as he apologized to victims and their families Wednesday before being sentenced to eight years in prison.
Nearly 80 people died and almost 800 were sickened in what’s considered the worst public health crisis in recent U.S. history. The fungal meningitis outbreak was caused by mold-tainted steroid injections produced by the New England Compounding Center.
Glen Chinn, who ran the so-called clean rooms where the drugs were made, sobbed as he struggled through his statement during his sentencing hearing in Boston’s federal courthouse. Chin said he knows some victims will never forgive him, but he’ll continue to pray that they will find some sort of peace.
“I realize these are just words and nothing will bring back your loved ones,” the 49-year-old said, occasionally turning to look directly at the victims and their relatives seated behind him. “But believe me when I say that I am truly sorry that this ever occurred,” he said.
Prosecutors wanted a 35-year-sentence for Chin, pointing to the devastating impact the outbreak had on families across the country. Chin’s lawyers asked for about three years behind bars.
Assistant U.S. Attorney Amanda Strachan relayed how a victim’s daughter said she heard her mother’s scream of pain from floors below when the daughter visited her mother in the hospital. The daughter compared the sound of her mother’s screams to the sound of the ship careening into the ocean in the movie “Titanic,” Strachan said.
“That’s the sound that she has in her head when she thinks about her mother’s death,” Strachan said. “It’s the sound made by Glenn Chin’s conduct.”
Mary Beth Krakowski of South Bend, Indiana, whose aunt died at age 88 after being injected with the contaminated drugs, told Chin he had a chance to be a “hero” and blow the whistle on the pharmacy’s dangerous practices.
“How did you get lost? How did you lose those ideals? How could you have fallen so far to become uncaring, cold and callous enough to put the patients’ welfare behind your personal gain?” asked Krakowski, the niece of Alice Machowiak.
Chin was convicted in October of racketeering and mail fraud but was cleared of second-degree murder, which could have brought a life sentence. He had had been charged with the deaths of 25 people in Florida, Indiana, Maryland, Michigan, North Carolina, Tennessee and Virginia.
Throughout his trial, prosecutors portrayed him as a callous employee who cut corners and ignored warning signs of unsafe production methods to boost production and profits.
Chin’s attorneys argued that he didn’t deserve more time behind bars than the pharmacy’s co-founder, Barry Cadden, who’s serving a nine-year sentence for his role in the outbreak. Cadden also was acquitted of second-degree murder.
Chin’s attorneys said Cadden was the one calling the shots and that Chin just couldn’t stand up to his boss. They said there was no evidence Chin caused the drugs to become contaminated.
“There is more to Glenn Chin than NECC,” attorney Stephen Weymouth told the judge, pointing to the dozens of letters written by friends and family that described him as a mentor and loving father to his two young children.
“This will be Glenn Chin’s own prison from which he will never be able to get out of for as long as he lives,” Weymouth said.
After the sentencing, victims expressed their dismay at what they considered to be a light sentence and the fact that neither Chin nor Cadden were convicted of murder.
“I want somebody in there blamed for the deaths,” said Willard Mazure, Jr., of Michigan, who became sickened after receiving an injection in 2012. “We’ve got 80 people dead, and nobody is responsible.”
The judge ordered Chin to report to prison in March.
The cambodian cure for resistant scabies mites
A member shares his story in how he was cured from resistant scabies mites in Cambodia. Where ivermectin and permethrin failed a local monk in a small town in Cambodia combated it with natural herbs and ancient remedies
Facebook group: Human Parasites Support Network
New Lyme disease tests could offer quicker, more accurate detection
New tests to detect early Lyme disease — which is increasing beyond the summer months -could replace existing tests that often do not clearly identify the infection before health problems occur.
In an analysis published on December 7 in Clinical Infectious Diseases, scientists from Rutgers University, Harvard University, Yale University, National Institute of Allergy and Infectious Diseases of the NIH and other academic centers, industry and public health agencies say new diagnostic methods offer a better chance for more accurate detection of the infection from the Lyme bacteria.
“New tests are at hand that offer more accurate, less ambiguous test results that can yield actionable results in a timely fashion,” said Steven Schutzer, a physician-scientist at Rutgers New Jersey Medical School and senior author. “Improved tests will allow for earlier diagnosis which should improve patient outcomes.”
Lyme disease is the most common tick-borne infection in North America and Europe. There are currently over 300,000 cases of Lyme disease annually in the United States alone and the disease is increasing and spreading into new regions. Lyme disease frequently, but not always, presents with a bull’s-eye rash. When the rash is absent, a laboratory test is needed.
The only FDA approved Lyme disease tests, based on technology developed more than two decades ago, rely on detecting antibodies that the body’s immune system makes in response to the disease. These antibody-based tests are the most commonly used tests for Lyme disease and are the current standard.
One problem, however, is that many people produce similar — called “cross-reactive” — antibodies in response to other bacteria not associated with Lyme disease, which causes confusing results and makes test accuracy more difficult.
“New tests are more exact and are not as susceptible to the same false-positive or false-negative results associated with current tests,” said Schutzer.
Schutzer and his colleagues say more accurate testing would help doctors decide when to prescribe the antibiotics used to clear the infection and help avoid severe long-term health problems. Antibody tests, can take three weeks or more for the antibody levels to reach a point where the tests can pick up a positive result.
Those involved in the paper joined forces after meeting at Cold Spring Harbor Laboratory’s Banbury Center, a nonprofit research institution in New York. The meeting organized and chaired by Schutzer and John A. Branda, assistant professor of pathology at Harvard Medical School, focused on current Lyme disease tests and new scientific advances made in increasing the accuracy of the diagnosis.
“This meeting and paper resulting from it are particularly significant,” said Jan Witkowski, professor in the Watson School of Biological Sciences at Cold Spring Harbor Laboratory who along with Nobel Laureate James Watson asked Schutzer to lead several symposia. “The participants noted that there are greatly improved diagnostic tests for Lyme disease that can be implemented now, and that the way is open to the development of further tests.”
- John A Branda, Barbara A Body, Jeff Boyle, Bernard M Branson, Raymond J Dattwyler, Erol Fikrig, Noel J Gerald, Maria Gomes-Solecki, Martin Kintrup, Michel Ledizet, Andrew E Levin, Michael Lewinski, Lance A Liotta, Adriana Marques, Paul S Mead, Emmanuel F Mongodin, Segaran Pillai, Prasad Rao, William H Robinson, Kristian M Roth, Martin E Schriefer, Thomas Slezak, Jessica Snyder, Allen C Steere, Jan Witkowski, Susan J Wong, Steven E Schutzer. Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. Clinical Infectious Diseases, 2017; DOI: 10.1093/cid/cix943
Possible new way to treat parasitic infections discovered
A chemical that suppresses the lethal form of a parasitic infection caused by roundworms that affects up to 100 million people and usually causes only mild symptoms has now been identified by researchers.
UT Southwestern Medical Center researchers have identified a chemical that suppresses the lethal form of a parasitic infection caused by roundworms that affects up to 100 million people and usually causes only mild symptoms.
“The approach we used could be applied generally to any nematode parasite, not just this one type,” said Dr. David Mangelsdorf, Chair of Pharmacology, an Investigator in the Howard Hughes Medical Institute (HHMI), and one of three corresponding authors of the study published in the Proceedings of the National Academy of Sciences. The study’s other corresponding authors are at two universities in Philadelphia.
“The plan is to develop better compounds that mimic the Δ7-dafachronic acid used in this study and eventually to treat the host to stop parasitic infection,” he added.
The Centers for Disease Control and Prevention (CDC) reports that the soil-dwelling Strongyloides stercoralis nematode, or roundworm, is the primary strongyloides species that infects humans. Experts estimate that between 30 million and 100 million people are infected worldwide, and most of them are unaware of it because their symptoms are so mild. The parasite can persist for decades in the body because of the nematode’s unique ability to reinfect the host, repeatedly going through the early stages of its life cycle. The nematode that causes the original infection exists in dirt on all continents except Antarctica, and it is most common in warmer regions, particularly remote rural areas in the tropics and subtropics where walking barefoot combined with poor sanitation leads to infection.
However, in people with compromised immune systems — such as those using long-term steroids for asthma, joint pain, or after an organ transplant — the mild form of the illness can progress to the potentially lethal form, a situation called hyperinfection. Studies indicate that mortality from untreated hyperinfection can be as high as 87 percent.
The World Health Organization reports that although the parasitic illness has almost disappeared in countries where sanitation has improved, children remain especially vulnerable in endemic regions due to their elevated contact with dirt. Further, the drug of choice, ivermectin, is unavailable in some affected countries.
“Ivermectin is used to treat the disease but is less effective in the lethal form of the infection,” said Dr. Mangelsdorf, a Professor of Pharmacology and Biochemistry. “We do not know exactly how the glucocorticoid [steroid] causes hyperinfection, but once it does, ivermectin is much less effective, prompting the search for new drugs. The new drug we used in our mouse model appears to be very effective,” he said.
To study the still unknown pathogenesis of the disease, the researchers developed a mouse model susceptible to the full range of infection by the human parasite. Because mice with intact immune systems are resistant to S. stercoralis infection, the researchers began with an immunocompromised strain of mice, and then exposed some to a synthetic steroid called methylprednisolone (MPA) that is commonly used to treat asthma in humans.
The mice were then exposed to the parasitic worms. Compared with untreated mice, those that received the steroid showed a tenfold increase in the number of parasitic female worms and a 50 percent increase in mortality, said Dr. Mangelsdorf, who holds both the Alfred G. Gilman Distinguished Chair in Pharmacology and the Raymond and Ellen Willie Distinguished Chair in Molecular Neuropharmacology in Honor of Harold B. Crasilneck, Ph.D.
In addition, third-stage larvae — the life cycle stage in which the worms can initiate hyperinfection — were found in higher numbers in the steroid-treated versus untreated mice, he added.
“Strikingly, treatment with a steroid hormone called Δ7-dafachronic acid, a chemical that binds to a parasite nuclear receptor called Ss-DAF-12, significantly reduced the worm burden in MPA-treated mice,” Dr. Mangelsdorf said. The Ss-DAF-12 receptor corresponds to a similar receptor in the long-studied C. elegans worm.
Dr. Mangelsdorf and colleagues previously showed (PNAS, 2009) that the DAF-12 receptor pathway is found in many parasitic species. They also showed that activating the receptor with Δ7-dafachronic acid could override the parasite’s development and prevent S. stercoralis from becoming infectious.
“Overall, this latest study provides a useful mouse model for S. stercoralis autoinfection and opens the possibility of new chemotherapy for hyperinfection by targeting the parasite’s own steroid hormone mechanism,” Dr. Mangelsdorf said.
- John B. Patton, Sandra Bonne-Année, Jessica Deckman, Jessica A. Hess, April Torigian, Thomas J. Nolan, Zhu Wang, Steven A. Kliewer, Amy C. Durham, James J. Lee, Mark L. Eberhard, David J. Mangelsdorf, James B. Lok, David Abraham. Methylprednisolone acetate induces, and Δ7-dafachronic acid suppresses,Strongyloides stercoralishyperinfection in NSG mice. Proceedings of the National Academy of Sciences, 2018; 201712235 DOI: 10.1073/pnas.1712235114
PARASITES2 weeks ago
A Deadly Roundworm Parasite Is Causing This Woman’s Painful Rashes
PARASITES2 weeks ago
Worms Are Eating My Lungs
PARASITES2 weeks ago
Fighting Resistant Scabies Mites
PARASITES2 weeks ago
The Human Parasites Support Network: Parasitic Infections
PARASITES2 weeks ago
Liver fluke live
PARASITES2 weeks ago
Fighting Schistosomiasis in Southern Lao PDR